Background Advanced prostate cancer remains one of the most common and deadly
cancers, despite advances in treatment options. Immunotherapy has provided little benefit to …

Abstract Purpose of Review Despite significant progress, patients with metastatic prostate
cancer continue to have poor prognosis. Immunotherapy has revolutionized cancer care for …

Prostate cancer is the second most common cause of cancer‐related death in men in the
United States and the fifth worldwide. Most prostate cancer arises as an androgen …

Therapeutic interventions to harness the immune system against tumor cells have provided
mixed results in the past for several solid tumors and hematologic malignancies. However …

It is becoming increasingly clear that inflammation influences prostate cancer (PCa)
development and that immune cells are among the primary drivers of this effect. This …

In the last few years, immunotherapy has become an important cancer treatment modality,
and although the principles of immunotherapy have evolved over many decades, the FDA …

Immunotherapy encompasses a wide range of therapies to engage the immune system to
target malignancies. In recent years, immunotherapy has made a major impact on treatment …

Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of
cancer related death in men in Western countries. The standard therapy for metastatic PCa …

Immunotherapy is rapidly transforming cancer care across a range of tumor types. Although
Sipuleucel-T represented the first successful vaccine for the treatment of established cancer …

In the last decade, immunotherapy has revolutionized the treatment landscape of several
hematological and solid malignancies, reporting unprecedented response rates …